The company is focused on developing and commercializing topical treatments for acne, androgenic alopecia, and genital warts, all of which have a large patient population and are primarily treated by dermatologists. Cassiopea's portfolio includes four clinical candidates, including Winlevi for acne, Breezula for AGA, CB-06-02 for genital warts, and CB-06-01 for acne.